IGF1 and neoplasm: According to the 13th acromegaly consensus statement by Giustina A et al. [13], the choice of a single or combination of medical therapies depends on the disease characteristics (tumour size and GH/IGF-1 levels), costs, preferred route of administration, and pre-existing comorbidities such as diabetes.